SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology

Rhea-AI Summary

SOPHiA GENETICS (NASDAQ: SOPH) and MD Anderson announced a strategic collaboration on January 7, 2026, to combine SOPHiA's AI analytics with MD Anderson's clinical expertise to accelerate AI-driven precision oncology.

The partners will co-develop an advanced next-generation sequencing oncology test built on the SOPHiA DDM™ Platform, create bioinformatics pipelines to interpret complex RNA-sequencing data, and launch R&D programs to track tumor evolution, improve genomic-test reproducibility, and match patients to clinical trials.

News Market Reaction

+4.17%

1 alert

+4.17% News Effect

On the day this news was published, SOPH gained 4.17%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $5.52 Vol: Volume 127,559 is 2.24x t...

high vol

$5.52 Last Close

Volume Volume 127,559 is 2.24x the 20-day average of 56,932, indicating elevated interest ahead of this AI partnership news. high

Technical Shares at $4.80 are trading above the 200-day MA ($3.66), reflecting a pre-existing upward trend.

Peers on Argus

Peers in Health Information Services showed mixed moves: HCAT +4.39%, LFMD +6.84...

1 Up

Peers in Health Information Services showed mixed moves: HCAT +4.39%, LFMD +6.84%, MNDR -4.33%, CCLD -2.99%, SLP +0.36%, suggesting SOPH’s reaction was more company-specific to this collaboration.

Historical Context

5 past events · Latest: Nov 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 11	NGS integration deal	Positive	+6.2%	Integration of MSK assays with DNBSEQ-T1+ for scalable precision oncology.
Nov 11	AI co-marketing deal	Positive	+6.2%	Co-marketing AI-powered MSK assays on DNBSEQ-T1+ for oncology research.
Nov 11	Sequencer partnership	Positive	+6.2%	Partnership with Element to pair AVITI systems with SOPHiA DDM analytics.
Nov 04	Q3 2025 earnings	Positive	-6.4%	Q3 results with 23% revenue growth and raised 2025 revenue guidance.
Oct 21	Earnings notice	Neutral	+0.2%	Announcement of upcoming Q3 2025 results and conference call schedule.

Pattern Detected

Partnership and AI-focused announcements have historically seen positive price alignment, while earnings with raised guidance previously coincided with a negative reaction.

Recent Company History

Over the past few months, SOPHiA GENETICS has repeatedly highlighted AI-enabled partnerships and operational progress. On Nov 11, 2025, multiple collaborations around SOPHiA DDM™ integration with DNBSEQ-T1+ and Element’s AVITI platforms all saw about a 6.21% positive move, reinforcing market interest in ecosystem expansion. Earlier, Q3 2025 results showed revenue of $19.5M (+23% YoY) with raised 2025 revenue guidance to $75–$77M, but the stock fell 6.4%. Today’s MD Anderson AI collaboration fits the pattern of strategically important, AI-centric partnerships.

Market Pulse Summary

This announcement highlights a strategic AI-driven collaboration with MD Anderson to co-develop a ne...

Analysis

This announcement highlights a strategic AI-driven collaboration with MD Anderson to co-develop a next-generation sequencing oncology test and bioinformatics pipelines for complex RNA data. It builds on prior AI and platform partnerships that previously drew positive market responses. Investors may watch for concrete milestones such as test deployment, adoption metrics, and any follow-on agreements that demonstrate how this collaboration scales across institutions and contributes to revenue growth.

Key Terms

next-generation sequencing, rna-sequencing, bioinformatics pipelines, precision oncology, +1 more

5 terms

next-generation sequencing medical

"co-developing an advanced next-generation sequencing oncology test."

Next-generation sequencing is a set of laboratory techniques that read large amounts of DNA or RNA quickly and cheaply by processing millions of short genetic fragments in parallel, rather than one at a time. For investors, it matters because faster, lower-cost genetic data powers drug discovery, diagnostic tests and personalized medicine, creating scalable revenue opportunities and competitive advantages for companies that own the technology or services.

rna-sequencing medical

"interpret complex RNA-sequencing data to guide diagnosis and treatment"

RNA sequencing is a laboratory method that reads which genes are active in cells by measuring their RNA messages, like listening to the passages a cell is reading from its instruction manual. For investors, it matters because the technique helps companies discover drug targets, develop diagnostics, select patients for trials, and show biological proof that a therapy is working — all factors that can speed development, reduce risk, and affect a biotech company's value.

bioinformatics pipelines technical

"create bioinformatics pipelines that enable clinicians to rapidly interpret"

A bioinformatics pipeline is an organized series of computer steps that processes raw biological data—like DNA or protein sequences—into useful results such as identified genes or patterns. Think of it as an automated factory line that cleans, analyzes and summarizes complex lab outputs so scientists can make decisions; for investors, pipeline quality affects how quickly and reliably a company can turn research into validated findings, regulatory submissions and potential revenue.

precision oncology medical

"advance research and precision oncology."In addition, MD Anderson and"

Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.

multimodal data technical

"translate complex multimodal data into actionable insights with greater"

Multimodal data is information that combines different types of sources—such as numbers, written reports, photos, audio, and sensor readings—into a single view. For investors it matters because blending these types is like looking at a company with both a microscope and a wide-angle lens: it can reveal risks, trends, or opportunities that a single type of data would miss, improving decision-making, forecasting, and due diligence.

AI-generated analysis. Not financial advice.

BOSTON and HOUSTON, Jan. 7, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice.

As part of the collaboration, MD Anderson and SOPHiA GENETICS are launching a series of research and development programs and co-developing an advanced next-generation sequencing oncology test. Built on the advanced AI algorithms of the SOPHiA DDM™ Platform, the new co-developed test aims to translate complex multimodal data into actionable insights with greater speed and scale. MD Anderson researchers will tap SOPHiA GENETICS' AI technologies to create bioinformatics pipelines that enable clinicians to rapidly interpret complex RNA-sequencing data to guide diagnosis and treatment for patients with cancer.

Donna Hansel, M.D., Ph.D., Division Head of Pathology and Laboratory Medicine at MD Anderson, said: "Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information. This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology."

In addition, MD Anderson and SOPHiA GENETICS will jointly launch a series of research and development programs to explore new ways to characterize tumor evolution in real time, to strengthen the reliability and reproducibility of complex genomic testing, and to enhance the ability to identify optimal clinical trials or research avenues for individual patients. This multi-layered program is designed to fuel next-generation scientific discovery, empowering clinicians and researchers with tools to better understand the dynamic nature of cancer. The collaborative work at MD Anderson will be led by Shashikant Kulkarni, Ph.D., deputy division head for Molecular Pathology, and J. Bryan, M.D., assistant professor, both in the Division of Pathology and Laboratory Medicine.

Philippe Menu, M.D., Ph.D., Chief Product Officer and Chief Medical Officer, SOPHiA GENETICS, said: "This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research. With SOPHiA DDM™ as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale."

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com, or connect on LinkedIn.

About SOPHiA GENETICS
SOPHiA GENETICS (NASDAQ: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn. 

About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution's sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation's first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report's "Best Hospitals" rankings and has been named one of the nation's top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-and-md-anderson-announce-strategic-collaboration-to-accelerate-ai-driven-precision-oncology-302654306.html

SOURCE SOPHiA GENETICS

FAQ

What did SOPH announce with MD Anderson on January 7, 2026?

SOPH announced a strategic collaboration with MD Anderson to co-develop an NGS oncology test and jointly run R&D programs using the SOPHiA DDM™ AI platform.

How will the SOPH and MD Anderson collaboration use RNA-sequencing data?

MD Anderson will use SOPH AI tools to build bioinformatics pipelines that help clinicians rapidly interpret complex RNA-sequencing results for diagnosis and treatment decisions.

What is the goal of the new NGS oncology test from SOPH and MD Anderson?

The test aims to translate multimodal sequencing data into actionable clinical insights with greater speed and scale using SOPHiA DDM™ algorithms.

Which MD Anderson leaders will oversee the collaboration work?

The collaborative work will be led by Shashikant Kulkarni, Ph.D., deputy division head for Molecular Pathology, and J. Bryan, M.D., assistant professor.

Will the SOPH–MD Anderson programs affect clinical trial matching for patients?

Yes, the R&D programs include efforts to enhance identification of optimal clinical trials or research avenues for individual patients.

Where can investors find more information about SOPH following the announcement?

Investors can visit SOPHiAGENETICS.com or follow the company on LinkedIn for additional details.